In late 2020, BD invested $1.2 billion for a four-year plan to boost its prefillable syringe manufacturing efforts because of mRNA innovations in vaccine technology.
About 70 percent of the top 100 pharmaceutical companies buy prefillable syringes from BD, and the new product will help finish-and-fill manufacturing efforts, according to the company.
Eric Borin, the president of BD’s pharmaceutical sector, said the product could help with dose-sparing, a new supply strategy used for monkeypox vaccines in which doses are split into fifths and the vaccines are administered closer to the top skin layer.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
